AAM, BMS ask FDA to acknowledge role of third parties in BA/BE studies
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesClinical Trials Regulation GenericsGuidancePharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)